David Facklam, MS has been appointed senior director, Regulatory and Scientific Affairs at CTI Clinical Trial and Consulting Services. Mr. Facklam has more than 30 years of experience in clinical drug development. Prior to joining the company, he held positions of increasing responsibility at Astellas Pharma, most recently serving as global head and vice president of Global Clinical Science. As a senior leader, he provided oversight and strategic input across clinical programs in transplantation, central nervous system, mycology, virology, urology, cardiology, hematology, and oncology. Mr. Facklam established the global clinical operations function at Astellas Pharma and was responsible for establishing key outsourcing strategic alliances.
“Dave has a deep scientific, analytical, and operational background, and he has direct experience leading complex global project teams to successful regulatory approvals,” said Lynn Fallon, president of CTI. “His expertise in global regulatory and drug development will be a great asset to CTI.”
CTI Appoints Regulatory and Scientific Affairs Director
By Kristin Brooks
Published December 12, 2013
blog comments powered by Disqus